BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26756883)

  • 21. The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.
    Thway K; Wang J; Wren D; Dainton M; Gonzalez D; Swansbury J; Fisher C
    Virchows Arch; 2015 Aug; 467(2):217-24. PubMed ID: 25912319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
    Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
    Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.
    Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM
    Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rhabdomyosarcoma in children - current pathologic and molecular classification.
    Dziuba I; Kurzawa P; Dopierała M; Larque AB; Januszkiewicz-Lewandowska D
    Pol J Pathol; 2018; 69(1):20-32. PubMed ID: 29895123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation.
    Wexler LH; Ladanyi M
    J Clin Oncol; 2010 May; 28(13):2126-8. PubMed ID: 20351321
    [No Abstract]   [Full Text] [Related]  

  • 27. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
    Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
    Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
    Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histology and fusion status in rhabdomyosarcoma.
    Rudzinski ER
    Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group.
    Aye JM; Chi YY; Tian J; Rudzinski ER; Binitie OT; Dasgupta R; Wolden SL; Hawkins DS; Gupta AA
    Pediatr Blood Cancer; 2020 May; 67(5):e28243. PubMed ID: 32124549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myc oncogene expression and nude mouse tumorigenicity and metastasis formation are higher in alveolar than embryonal rhabdomyosarcoma cell lines.
    Kouraklis G; Triche TJ; Wesley R; Tsokos M
    Pediatr Res; 1999 Apr; 45(4 Pt 1):552-8. PubMed ID: 10203148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of FOXO1 break-apart status by fluorescence in situ hybridization in atypical alveolar rhabdomyosarcoma.
    Fu L; Jin Y; Jia C; Zhang J; Tai J; Li H; Chen F; Shi J; Guo Y; Ni X; He L
    Sci China Life Sci; 2017 Jul; 60(7):721-728. PubMed ID: 28646473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
    Barr FG; Duan F; Smith LM; Gustafson D; Pitts M; Hammond S; Gastier-Foster JM
    Genes Chromosomes Cancer; 2009 Aug; 48(8):661-72. PubMed ID: 19422036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
    Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.
    Anderson JR; Barr FG; Hawkins DS; Parham DM; Skapek SX; Triche TJ
    J Clin Oncol; 2010 Oct; 28(29):e587-8; author reply e589-90. PubMed ID: 20697086
    [No Abstract]   [Full Text] [Related]  

  • 39. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.
    Barr FG; Smith LM; Lynch JC; Strzelecki D; Parham DM; Qualman SJ; Breitfeld PP
    J Mol Diagn; 2006 May; 8(2):202-8. PubMed ID: 16645206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.